Guerbet, a global leader in medical imaging, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1926, the company has established itself as a pioneer in the development of contrast agents and medical imaging solutions, marking significant milestones in innovation and technology throughout its history. Specialising in imaging products for radiology and interventional imaging, Guerbet offers a diverse portfolio that includes contrast media, injectors, and software solutions. Their commitment to quality and safety sets them apart in the industry, ensuring optimal patient care and enhanced diagnostic accuracy. With a strong market position, Guerbet continues to achieve notable advancements, reinforcing its reputation as a trusted partner in the healthcare sector.
How does Guerbet's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Guerbet's score of 13 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Guerbet, headquartered in France, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets. Guerbet aims to reduce its absolute Scope 1 and Scope 2 GHG emissions by approximately 27.5% by 2032, using 2021 as the baseline year. Additionally, the company is committed to a 13.5% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, fuel and energy activities, upstream transportation and distribution, waste generated in operations, and downstream transportation and distribution, also by 2032. These targets align with the Science Based Targets initiative (SBTi) and are classified as consistent with the reductions necessary to limit global warming to well below 2°C. Guerbet's proactive approach reflects its commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector, positioning the company as a responsible player in addressing climate change.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guerbet is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.